Skip to main content
Clinical Trials/ACTRN12618001064291
ACTRN12618001064291
Recruiting
未知

EST4E Non-invasive Preimplantation Genetic Screening (PGS) testing for IVF patient embryos that are not suitable for standard biopsy to determine the proportion of embryos that are unable to be screened using standard PGS that can be conclusively screened for aneuploidy using NEST4E by analysing cell-free DNA in the embryo culture media.

Repromed0 sites73 target enrollmentJune 26, 2018

Overview

Phase
未知
Intervention
Not specified
Conditions
Infertility
Sponsor
Repromed
Enrollment
73
Status
Recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 26, 2018
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Repromed

Eligibility Criteria

Inclusion Criteria

  • 1\.Any patient for whom PGS is considered as a treatment option will be eligible
  • 2\.Patients that have blastocysts’ that are not suitable for standard biopsy and PGS.
  • Under the current Ethical guidelines on the use of assisted reproductive technology in clinical practice and research (2017\), only patients that have already consented to the use of PGT to select against a genetic condition, disease or abnormality will be approached in this study. This is to recognise that the decision to have genetic testing requires serious ethical consideration and is to prevent patients consenting to this trial to access this technology without having considered the full ethical implications.

Exclusion Criteria

  • 1\.Patients involved in the Donor program (oocyte and sperm)
  • 2\.Patients with a known infectious disease (HIV, HEP B, HEP C)
  • 3\.Patients using Preimplantation Genetic Diagnosis (PGD) for single genes or translocations.

Outcomes

Primary Outcomes

Not specified

Similar Trials